Skip to main content
SpringerLink
Log in

Polymyalgia rheumatica

Was ist der aktuelle Stand?

Polymyalgia rheumatica

What is the current status?

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Die Diagnose der Polymyalgia rheumatica (PMR) basiert auf der typischen Klinik und den erhöhten Entzündungsparametern im Blut. Allerdings sind beide unspezifisch. Daher stellt die gute Differenzialdiagnose der Erkrankung auch heute noch eine Herausforderung für den Kliniker dar. Offensichtlich tragen die neuen 2012 formulierten Konsensus-Klassifikationskriterien von European League Against Rheumatism (EULAR) und American College of Rheumatology (ACR) zu einer verbesserten Diagnostik der PMR sowohl hinsichtlich Sensitivität (92,6 %) als auch Spezifität (91,2 %) bei. Als Standardtherapie gelten nach wie vor Glukokortikoide und alternativ auch Methotrexat und möglicherweise in Zukunft auch eine Anti-IL-6-Therapie.

Abstract

The diagnosis of polymyalgia rheumatica (PMR) is based on the typical clinical symptoms and elevated inflammatory markers in blood; however, both are unspecific and the differential diagnosis of the disease still represents a challenge for clinicians. The new consensus classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established in 2012 have a high sensitivity (92.6 %) and specificity (91.2 %) and therefore contribute to improved diagnostics. Glucocorticoids are still the standard treatment with methotrexate and as an alternative and possibly anti-interleukin (anti-IL) 6 therapy in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Salvarini C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234–245

    Article  Google Scholar 

  2. Dasgupta B, Cimmino MA, Kremers HM et al (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484–492

    Article  PubMed Central  PubMed  Google Scholar 

  3. Doran MF, Crowson CS, O’Fallon WN (2002) Trends in the incidence of polymyalgia rheumatic over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29:1694–1697

    PubMed  Google Scholar 

  4. Smeeth L, Cook C, Hall AJ (2006) Incidence of diagnosed polymalgia rheumatica and temporal arteritis in the United Kingdom 1990–2001. Ann Rheum Dis 65:1093–1098

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Boesen P, Sorensen SF (1987) Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A propective investigation, 1982–1985. Arthritis Rheum 30:294–299

    Article  CAS  PubMed  Google Scholar 

  6. Elling P, Olsson AT, Elling H (1996) Synchronous variations of the incidience of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 23:112–119

    CAS  PubMed  Google Scholar 

  7. Schaufelberger C, Bengtsson BA, Andersson R (1995) Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 34:261–264

    Article  CAS  PubMed  Google Scholar 

  8. Pamuk ON, Donmez S, Karahan B et al (2009) Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data. Clin Exp Rheumatol 27:830–833

    CAS  PubMed  Google Scholar 

  9. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M et al (1999) The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 26:1326–1332

    CAS  PubMed  Google Scholar 

  10. Salvarani C, Cantini F, Olivieri I et al (1997) Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 127:27–31

    Article  CAS  PubMed  Google Scholar 

  11. Frediani B, Falsetti P, Storri L et al (2002) Evidence for synovitis in active polymyalgia rheumatica: sonographic study in aölarge series of patients. J Rheumatol 29:123–130

    PubMed  Google Scholar 

  12. Cantini F, Salvarni C, Olivieri I et al (2001) Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 28:1049–1055

    CAS  PubMed  Google Scholar 

  13. Salvarani C, Barozzi L, Cantini F et al (2008) Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 67:758–761

    Article  CAS  PubMed  Google Scholar 

  14. Blockmans D, De Ceuninck L, Vanderschueren S et al (2007) Repetitive 18-fluorodesoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 46:672–677

    Article  CAS  PubMed  Google Scholar 

  15. Meliconi R, Pulsatelli L, Uguccioni M et al (1996) Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 39:3768–3775

    Article  Google Scholar 

  16. Kreiner F, Langberg H, Galbo H (2010) Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 62:3768–3775

    Article  PubMed  Google Scholar 

  17. Weyand CM, Fulbright JW, Hunder GG et al (2000) Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43:1041–1048

    Article  CAS  PubMed  Google Scholar 

  18. Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C et al (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69:263–269

    Article  CAS  PubMed  Google Scholar 

  19. Straub RH, Cutolo M (2006) Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica. J Rheumatol 33:1219–1223

    PubMed  Google Scholar 

  20. Cantini F, Salvarani C, Olivieri I (1998) Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica. Ann Intern Med 128:1326–1332

    Article  Google Scholar 

  21. Bird HA, Esselinckx W, Dixon AS et al (1979) An evaluation of criteria for polymalgia rheumatica. Ann Rheum Dis 38:434–439

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Jones JG, Hazleman BL (1981) Prognosis and management of polymyalgia rheumatic. Ann Rheum Dis 40:1–5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Chuang T-Y, Hunder GG, Ilstrup DM et al (1982) Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 97:672–680

    Article  CAS  PubMed  Google Scholar 

  24. Healey L (1984) Long-term follow up of polymalgia rheumatic: evidence for synovitis. Semin Arthritis Rheum 13:322–328

    Article  CAS  PubMed  Google Scholar 

  25. Nobunaga M, Yoshioka K, Yasuada M et al (1989) Clinical studies of polymyalgia rheumatica: a proposal of diagnostic criteria. Jpn J Med 28:452–456

    Article  CAS  PubMed  Google Scholar 

  26. Weigand S, Ehrenstein B, Fleck M, Hartung W (2014) Joint involvement in patients with early polymyalgia rheumatica using high-resolution ultrasound and its contribution t the EULAR/ACR 2012 classification criteria for polymyalgia rheumatic. J Rheumatol 41:730–734

    Article  PubMed  Google Scholar 

  27. Macchioni P, Boiardi L, Catanoso M et al (2014) Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-center study. Ann Rheum Dis 73:1190–1193

    Article  PubMed  Google Scholar 

  28. Matteson EL, Maradit-Kremers H, Cimmino MA et al (2012) Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol 39:795–803

    Article  PubMed  Google Scholar 

  29. Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493–500

    Article  CAS  PubMed  Google Scholar 

  30. Macchioni P, Boiardi L, Catanoso M et al (2013) Tocilizumab for polymyalgia rheumatic: a report of two cases and review of the literature. Semin Arthritis Rheum 43:113–118

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Seitz gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Universitätsklinik für Rheumatologie, Immunologie & Allergologie, Inselspital, Freiburgstrasse 18, 3010, Bern, Schweiz

    M. Seitz

Authors
  1. M. Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Seitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seitz, M. Polymyalgia rheumatica. Z Rheumatol 74, 507–510 (2015). https://doi.org/10.1007/s00393-014-1548-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1548-z

Schlüsselwörter

Keywords

Search

Navigation